Abstracts tagged "autoimmune diseases"

Abstract Number: 1580 • ACR Convergence 2024
Overt Polyautoimmunity and Its Risk Factors in a Multicenter Cohort of Systemic Sclerosis Patients
Irene Carrión-Barberà¹, Laura Tío², Laura Triginer², María Lee², Alfredo Guillén-del Castillo³, Anna Ribes², Lidia Valencia Muntalà⁴, Jordi Monfort¹, Tarek Carlos Salman Monte:⁵, Carmen PIlar Simeón-Aznar³, Anna Pros¹ and Javier Narvaez-García⁶, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar Research Institute, Barcelona, Spain, ³Hospital Vall d'Hebron, Barcelona, Spain, ⁴Hospital de Bellvitge, Barcelona, Spain, ⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Overt PolyA (the clinical coexistence of ≥2 autoimmune diseases (AID) that fulfill classification criteria), is a frequent phenomenon in systemic sclerosis (SSc). However, the…
Abstract Number: 1726 • ACR Convergence 2024
Safety, Cancer Progression, and Autoimmune Disease Activity in Patients with Pre-Existing Autoimmune Disease Undergoing CD19 CAR T Cell Therapy for Lymphoma: A Retrospective Comparative Cohort Study
Kathleen Vanni¹, Kaitlin McCarter¹, Xiaosong Wang², Caitlyn Duffy³, Jamie Dela Cruz³, Holly Wobma⁴, Sarah Nikiforow³, Elena Massarotti¹, Karen Costenbader⁵, Jessica Little¹, Ellen Gravallese⁶, Gregory McDermott⁷, Caron Jacobson³ and Jeffrey Sparks⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Dana Farber Cancer Institute, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁷Brigham and Women's Hospital, Brookline, MA, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: CD19-targeted chimeric antigen receptor (CAR) T cell therapy is FDA-approved to treat lymphoma. A recent prospective case series of CD19 CAR T cell therapy…
Abstract Number: 1832 • ACR Convergence 2024
Targeting Hippo Pathway Diminishes Disease Signaling in Scleroderma Skin
Olesya Plazyo¹, Rachael Wasikowski², Mehrnaz Gharaee-Kermani¹, Eliza Pei-Suen Tsou¹, Lam Tsoi¹, Allison Billi¹, J. Michelle Kahlenberg¹, John Varga¹, Johann Gudjonsson¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan, Dept. of Dermatology, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc), a female-biased autoimmune disease that causes inflammation and fibrosis in skin and internal organs, lacks effective treatment options. Our previous work, including…
Abstract Number: 1919 • ACR Convergence 2024
Patient-reported Social Risk Factor Screening Among Rheumatology Outpatients
Alissa Chandler¹, Mohammed Hamid², Aurora Jiao³, Kelsey Hulcher⁴, Isha Sharma⁵, Patrice Odom⁴, Andrew Robinson⁶, Sara Kellahan², Maura Kepper⁷, Colleen Dostal⁸, Senada Fenelon⁹, Seth Eisen¹⁰, Daphne Lew¹¹ and Alfred Kim¹², ¹Washington University, St. Louis, MO, ²Washington University School of Medicine, St. Louis, MO, ³Washington University, Saint Louis, ⁴Washington University, Saint Louis, MO, ⁵Washington University in St. Louis School of Medicine, San Jose, CA, ⁶Washington University, Fenton, MO, ⁷Washington University, Brown School of Social Work, Saint Louis, ⁸Southern Illinois University Edwardsville, St. Louis, MO, ⁹Washington University St Louis, Ballwin, MO, ¹⁰Washington University School of Medicine, St Louis, MO, ¹¹Center for Biostatistics and Data Science, Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine and Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO
Background/Purpose: The purpose of this study was to pilot test a patient-reported social risk factor (SRF) screening tool among rheumatology outpatients and to examine the…
Abstract Number: 2049 • ACR Convergence 2024
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Dongze Wu¹ and Yingzhao jin², ¹Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China (People's Republic), ²Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…
Abstract Number: 2307 • ACR Convergence 2024
Deep Spatial Profiling Unveils Dominant Double Negative B Cells in Severe Forms of Sjögren’s Syndrome
Loukas chatzis¹, Patrice Hemon², Yvonne Scuiller³, Andreas Goules⁴, Divi Cornec⁵, Athanasios Tzioufas⁶ and Jacques-Olivier Pers³, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²LBAI, UMR1227, Univ Brest, INSERM, Brest, France, Paris, ³LBAI, UMR1227, Univ Brest, INSERM, Brest, France, Paris, France, ⁴GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁵Service de Rhumatologie, CHU de Brest, Brest, France, ⁶LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Imaging mass cytometry (IMC) is a powerful high throughput technique that enables in-situ multiparametric analysis of a single fixed tissue section while preserving spatial…
Abstract Number: 2474 • ACR Convergence 2024
High-throughput Screening Identifies Specific Molecular Markers for ILD in Patients with Rheumatic Diseases
Anna-Maria Hoffmann-Vold¹, Vyacheslav Palchevskiy², Phuong Phuong Diep³, Henriette Didriksen¹, Mona Lovise Talaro Ramsli¹, Jin Zhou⁴, Shahrzad Lari⁴, Elena Pachera⁵, Michael T Durheim¹, Øyvind Molberg⁶, Oliver Distler⁷, S. Samuel Weigt² and John A Belperio⁴, ¹Oslo University Hospital, Oslo, Norway, ²University of California Los Angeles, Los Angeles, CA, ³Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ⁴University of California Los Angeles, Los Angeles, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Molecular expression patterns of lung tissue across rheumatic musculoskeletal diseases (RMDs) have not been extensively studied. Lung sampling is invasive and not always practical…
Abstract Number: 2614 • ACR Convergence 2024
Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Ana Milena Gil¹, Julián Barahona-Correa², Jorge Bruce Flórez-Suárez³, Daniel Fernández-Ávila⁴ and Zulma Cucunubá¹, ¹Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia, ²Division of Rheumatology, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia, ³Department of Immunology, Universidad Nacional de Colombia, Bogotá, Colombia, ⁴5Hospital San Ignacio, Colombia, BOGOTA, Colombia
Background/Purpose: The association between SARS-CoV-2 infection and the new onset of immune-mediated diseases is a topic of interest given the conflicting evidence available. This systematic…
Abstract Number: 0084 • ACR Convergence 2024
DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
Xi Li, bing Li, Jun Yao, bin zhang, zhongyuan zhu, yang Qiu and haiqing Hua, Duality Biologics Ltd, Shanghai, China (People's Republic)
Background/Purpose: BDCA2 (blood dendritic cell antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), whose over-production of type I interferon (IFN-I) is crucial in…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
Abstract Number: 0304 • ACR Convergence 2024
Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio
doryan Garcia Olivas¹, Judith Hernández Sánchez¹, luis Bausá Gimeno¹, Javier Nóvoa Medina¹, Sergio Machín¹, Maria Ángeles Acosta-Mérida¹, Diana Botello-Corzo¹, daniel Batista Perdomo¹, José Ángel Hernández Beriain² and Beatriz Tejera Segura¹, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, ²Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
Abstract Number: 0436 • ACR Convergence 2024
Family Planning in Rheumatology: A Single Center Quality Improvement Project
Sara Heard, Elena Cravens, Jeanne Gosselin and Juvena Hitt, University of Vermont Medical Center, Burlington, VT
Background/Purpose: Pregnancy in patients with rheumatologic disease can lead to serious maternal and fetal complications. Multinational surveys have shown that medical providers often fail to…
Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Oliver Distler¹, Margarida Alves², Gerrit Toenges³ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Yan Zhang¹, Brittany Ross¹, Diana Galvan¹, Yanjie Bao¹, Daiki Matsuda¹, Shaun Grosskurth¹, Iago Pinal-Fernandez², Maria Casal-Dominguez³, Gregor Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian Bot¹, Andrew Mammen² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²NIH, Bethesda, MD, ³NIH, Bathesda, MD
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
Abstract Number: 0908 • ACR Convergence 2024
Clinical Characteristics of Patients with High SLE-specific and High Multitrait Polygenic Risk – an Investigation of SLE Risk Loci
Nina Oparina¹, Sarah Reid², Ahmed Sayadi³, Maija-Leena Eloranta⁴, Martina Frodlund⁵, Karoline Lerang⁶, Andreas Jönsen⁷, Solbritt Rantapaa-Dahlqvist⁸, Anders Bengtsson⁷, Anna Rudin⁹, Øyvind Molberg¹⁰, Christopher Sjowall¹¹, Lars Rönnblom⁴ and Dag Leonard⁴, ¹UU, Uppsala, Sweden, ²Uppsala University, Medical Sciences, Uppsala, Sweden, ³Uppsala, Uppsala, Sweden, ⁴Uppsala University, Uppsala, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶Oslo University, Oslo, Norway, ⁷Lund University, Lund, Sweden, ⁸Umeå University, Umeå, Sweden, ⁹Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹⁰Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹¹Linköping University, Linköping, Sweden
Background/Purpose: Heritability of SLE is high and more than 200 genetically associated SLE risk loci were identified. Part of them are specific and associate with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].